Literature DB >> 10189274

Link between drug absorption solubility and permeability measurements in Caco-2 cells.

V Pade1, S Stavchansky.   

Abstract

The objective of this investigation was to establish a relationship between drug permeability and solubility in vitro and the extent of drug absorption in humans. We selected drugs with varying permeabilities and solubilities with the aim of establishing a relationship between permeability and solubility measurements in vitro and the extent of absorption in vivo. Effective permeability coefficients of the model drugs (naproxen, phenytoin, propranolol, diltiazem, salicylic acid, ephedrine, cimetidine, chlorothiazide, and furosemide) at 37 degrees C and pH 7.2 were estimated using the Caco-2 cell line. Saturation solubilities of the model drugs were estimated at pH 7.2 and at 37 degrees C. Data obtained from the permeability and solubility experiments were employed in classifying the drugs into high and low permeability-solubility groups. The permeability coefficients ranged from 1x10(-7) to 4x10(-5) cm/s, and a good correlation was observed between the permeability coefficients in Caco-2 cells and percent absorbed in humans. Drugs in the high permeability, high solubility class are completely absorbed (90% or higher). The study results indicate that there is a strong link between permeability measured in Caco-2 cells, solubility, and fraction of drug absorbed in humans.

Entities:  

Mesh:

Year:  1998        PMID: 10189274     DOI: 10.1021/js980111k

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  29 in total

1.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

3.  Intestinal absorption of miltefosine: contribution of passive paracellular transport.

Authors:  Cécile Ménez; Marion Buyse; Christophe Dugave; Robert Farinotti; Gillian Barratt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

4.  Permeation of four oral drugs through human intestinal mucosa.

Authors:  Erina Pretorius; Patrick J D Bouic
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

5.  Insights into the permeability of drugs and drug-like molecules from MI-QSAR and HQSAR studies.

Authors:  Ranajit N Shinde; K Srikanth; M Elizabeth Sobhia
Journal:  J Mol Model       Date:  2011-06-03       Impact factor: 1.810

6.  In situ artificial membrane permeation assay under hydrodynamic control: permeability-pH profiles of warfarin and verapamil.

Authors:  Matej Velický; Dan F Bradley; Kin Y Tam; Robert A W Dryfe
Journal:  Pharm Res       Date:  2010-05-07       Impact factor: 4.200

Review 7.  Getting Drugs Across Biological Barriers.

Authors:  Rong Yang; Tuo Wei; Hannah Goldberg; Weiping Wang; Kathleen Cullion; Daniel S Kohane
Journal:  Adv Mater       Date:  2017-07-28       Impact factor: 30.849

8.  Computational approaches for modeling human intestinal absorption and permeability.

Authors:  Govindan Subramanian; Douglas B Kitchen
Journal:  J Mol Model       Date:  2006-04-01       Impact factor: 1.810

9.  Optimisation of the caco-2 permeability assay using experimental design methodology.

Authors:  Mark Lakeram; David J Lockley; Ruth Pendlington; Ben Forbes
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

10.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.